We see what others don't

About Mundipharma

Opens Page

Our medicines

Opens Page

Careers

Opens Page

Partnering

Opens Page

Latest News

Mundipharma International welcomes positive phase III efficacy findings for Invokana® (canagliflozin) in type 2 diabetes patients with chronic kidney disease

Jul 20 2018

Opens Page

INFORMATION FOR EUROPEAN MEDICAL/TRADE MEDIA ONLY

What the patient access experts are saying

Jun 18 2018

Opens Page

BY WILL DUNLOP, HEAD OF MARKET ACCESS, MUNDIPHARMA INTERNATIONAL

Herzuma® (trastuzumab), a biosimilar for the treatment of breast cancer, now available in Europe

May 03 2018

Opens Page

FOR EUROPEAN MEDICAL/TRADE MEDIA ONLY


The Mundipharma global network of
independent associated companies:

 

Active in more than 
120 worldwide markets;
30 in Europe

 

A presence across
six continents
.

 

Together, these businesses
employ more than
8,600 professionals

 

European sales exceeding
€1 billion and global sales
exceeding $3.4 billion

Supporting patients and communities

As we live longer, providing good quality medical care becomes an increasingly challenging task for the healthcare sector.

Network capabilities

Since our founding by physician entrepreneurs in 1952, the Mundipharma network of independent associated pharmaceutical companies has served the needs of patients and healthcare providers around the globe by providing novel medicines that address unmet medical needs.

Sharing clinical trial information and results

Clinical trial results for studies managed by Mundipharma Research and more information on our disclosure policy are available here.